opera news

download from google play download from apple store

Pull to refresh

Pull to refresh

Pull to refresh

Pull to refresh

Pull to refresh

Pull to refresh

Pull to refresh

Pull to refresh

Pull to refresh

Pull to refresh

Pull to refresh

Pull to refresh

Connection failed Try again

opera news

download from google play download from apple store

Scientists find a better drug for blinding eye disease in older people

Knowridge Science Report 1d

"\u003Chtml\u003E\n \u003Chead\u003E\u003C\u002Fhead\u003E\n \u003Cbody\u003E\n \u003Cdiv\u003E\n \u003Cdiv\u003E\n \u003Cdiv\u003E\n \u003Cdiv\u003E \n \u003Cdiv\u003E \n \u003Cfigure\u003E\n \u003Cspan class=\"view-HD-pictures-wrap\"\u003E\n \u003Cimg class=\"view-HD-pictures\" data-src=\"https:\u002F\u002Fres.6chcdn.feednews.com\u002Fassets\u002Fv2\u002F77fcf135948e43213627b1c96c8848ee?source=nlp&quality=uhq&format=jpeg&resize=720\" alt=\"\" title=\"Scientists find a better drug for blinding eye disease in older people\" data-image-width=\"696\" data-image-height=\"445\"\u003E\n \u003Cspan class=\"view-HD-pictures\"\u003EView pictures in App save up to 80% data.\u003C\u002Fspan\u003E\n \u003C\u002Fspan\u003E\n \u003Cfigcaption\u003E\n Credit: Engin Akyurt\u002F Pexels\n \u003C\u002Ffigcaption\u003E\n \u003C\u002Ffigure\u003E \n \u003C\u002Fdiv\u003E \n \u003Cp\u003EAge-related macular degeneration (AMD) is the most common cause of vision loss among people aged 50 and older, affecting an estimated 7.3 million individuals in the United States.\u003C\u002Fp\u003E \n \u003Cp\u003EOf these patients, 1.75 million have advanced AMD and will lose vision from this condition.\u003C\u002Fp\u003E \n \u003Cp\u003EThis includes patients with the “wet” form of AMD, characterized by the growth of abnormal blood vessels in the retina that can bleed or leak damaging fluids into the central portion of this light-sensing tissue.\u003C\u002Fp\u003E \n \u003Cp\u003EIn a study from Johns Hopkins Medicine, scientists found commonly used AMD drug outperforms another at weaning patients off treatment at one year.\u003C\u002Fp\u003E \n \u003Cp\u003EStandard treatment of wet AMD requires monthly or bimonthly eye injections of drugs that slow or stop the growth of these leaky blood vessels, and in most cases, stave off further vision loss.\u003C\u002Fp\u003E \n \u003Cp\u003EIn addition to the cost, discomfort and rare but potential risk of retinal detachment, infection and other side effects, the need to return to a physician’s office or clinic each month for these injections is a common barrier to consistent care, leading to missed treatments and potentially worsening vision.\u003C\u002Fp\u003E \n \u003Cp\u003EAflibercept and bevacizumab are the two most frequently used therapies for the treatment of wet AMD.\u003C\u002Fp\u003E \n \u003Cp\u003EIn the study, researchers examined 106 patients with “wet” AMD and found that nearly half of patients treated with aflibercept could safely stop eye injection therapy after one year without further vision loss.\u003C\u002Fp\u003E \n \u003Cp\u003EOnly 17% of patients taking another commonly used wet AMD therapy, bevacizumab, were able to safely wean from the drug at a year.\u003C\u002Fp\u003E \n \u003Cp\u003EThe findings build on evidence from a previous study led by the researchers that found potentially a third of patients with wet AMD could safely pause therapy after one year of monitoring by a physician.\u003C\u002Fp\u003E \n \u003Cp\u003EThe results suggest that if doctors can match the right patient to the best therapy, many patients with macular degeneration may not need lifelong therapy.\u003C\u002Fp\u003E \n \u003Cp\u003EThese results provide additional evidence that aflibercept and bevacizumab should not be considered interchangeable when treating AMD.\u003C\u002Fp\u003E \n \u003Cp\u003EThe team says clinical trials of a larger group of patients will be necessary to confirm their findings.\u003C\u002Fp\u003E \n \u003Cp\u003EIf you care about eye health, please read studies that \u003Ca href=\"https:\u002F\u002Fknowridge.com\u002F2022\u002F08\u002Fdiabetes-high-blood-pressure-can-predict-blinding-eye-disease\u002F\"\u003Ediabetes and high blood pressure can predict blinding eye disease\u003C\u002Fa\u003E, and \u003Ca href=\"https:\u002F\u002Fknowridge.com\u002F2022\u002F08\u002F7-habits-that-help-prevent-vision-loss-in-older-people-2\u002F\"\u003E7 habits that help prevent vision loss in older people.\u003C\u002Fa\u003E\u003C\u002Fp\u003E \n \u003Cp\u003EFor more information about eye health, please see recent studies about \u003Ca href=\"https:\u002F\u002Fknowridge.com\u002F2021\u002F11\u002Fhow-to-protect-your-eyes-from-diabetes\u002F\"\u003Ehow to protect your eyes from diabetes\u003C\u002Fa\u003E, and results showing that \u003Ca href=\"https:\u002F\u002Fknowridge.com\u002F2021\u002F07\u002Fvitamin-b3-may-help-treat-common-blinding-eye-disease\u002F\"\u003Evitamin B3 may help treat common blinding eye disease\u003C\u002Fa\u003E.\u003C\u002Fp\u003E \n \u003Cp\u003EThe study was conducted by Akrit Sodhi et al and published in the \u003Cem\u003EJournal of Clinical Investigation.\u003C\u002Fem\u003E\u003C\u002Fp\u003E\n \u003C\u002Fdiv\u003E\n \u003C\u002Fdiv\u003E\n \u003C\u002Fdiv\u003E\n \u003C\u002Fdiv\u003E\n \u003C\u002Fbody\u003E\n\u003C\u002Fhtml\u003E"

Follow us on Telegram